Lin Shao-Lee's Form 4 filing
Cue Biopharma, Inc. (CUE) · filed Jun 3, 2026
- Accession no.
- 0001725092-26-000004
- Filed
- Jun 3, 2026
- Trade date
- Jun 1, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 2 derivative transactions. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001725092-26-000009 (Jul 30, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lin Shao-LeeCIK 0001725092 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | PPurchaseAcquired | +90,906 | $11.00 | +$999,966 | 90,906 | Indirect | |
| Jun 1, 2026 | Common Stock | PPurchaseAcquired | +45,453 | – | – | 45,453 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.